US Women's Health · 2012 – 2026
click on the drops to reveal facts · 0 / 20 revealed
scroll
For decades, hormone therapy was standard care. Women got prescriptions. Doctors wrote them. It wasn't controversial — it worked. Then in July 2002, a federal study called the Women's Health Initiative released preliminary results. The press reported a single headline: HRT causes cancer. Doctors stopped prescribing overnight. Women were left without treatment, without explanation, and without anyone willing to revisit the question.
What follows is the story of five forces — community, capital, pharma, research, policy — each one building the conditions that made the next one possible. Each scroll below is a "because of that." The reckoning wasn't an event. It was assembled.
Because doctors had stopped prescribing and nobody was correcting the record, women had nowhere to go. So in 2012, eleven of them went to Reddit. No funding. No press. No institutions. Just women who couldn't get straight answers building a library of answers for each other — symptoms, dosages, doctors who actually listened, what the research actually said.
A sister community, r/Perimenopause, named and documented a transition the medical system didn't have a clean category for. By 2026, the two communities had nearly 490,000 members combined. That signal — documented, public, undeniable — was the prior condition that made everything else possible.
Member counts: Reddit public data · r/Menopause + r/Perimenopause live subscriber counts, June 2026 · Growth curve: Wayback Machine archive snapshots 2012–2026, subreddit analytics extrapolation · Community founding: r/Menopause subreddit history, 2012
Because 50,000 women had documented their symptoms in public for eight years, the signal finally became too large for venture capital to ignore. A pandemic normalized telehealth. Founders who had lived the problem started building. In 2020, the money moved. Maven, Midi, Evernow, Flo — companies that hadn't existed a few years earlier raised hundreds of millions in months.
That eight-year gap — between the community's signal and capital's response — is the gap that defined how many women went without care. The money didn't discover menopause. It arrived after everything else had built the road.
Because capital validated the market, pharma had reason to reinvest in the drugs.
Funding rounds: Crunchbase · PitchBook · company press releases (Midi Health, Alloy Health, Winona, Elektra Health, Evernow, Maven Clinic) · Market sizing: McKinsey & Company FemTech Market Report 2022; Deloitte Women's Health Insights 2024; Grand View Research Menopause Market Forecast 2024–2030 · VC trends: Rock Health Digital Health Funding 2020–2026; PitchBook FemTech Report Q1 2026
Because a single misread study had encoded fear into prescribing for twenty years, there was no new drug investment, no new research, no new approvals — for over a decade. Then the community signal grew loud enough, and the capital wave followed, and pharma finally had both a business case and a corrected scientific record. HRT prescriptions are rising again. The first non-hormonal treatments in history were approved in 2023 and 2025. The FDA removed the black box warning in November 2025 — 23 years after it went up. The chart below is what the collapse and slow return looks like mapped against time.
Prescription volume: IQVIA (formerly IMS Health) National Prescription Audit · U.S. HRT dispenses 1995–2024 · Rossouw et al., "Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women," JAMA 2002 (WHI study triggering the 2002 collapse) · Menopause Society (formerly NAMS) Clinical Practice Guidelines 2022 · FDA actions: Veozah (fezolinetant) approval May 2023 · Alyssa (elinzanetant) approval March 2025 · black-box warning removal November 2025 (Federal Register Vol. 90) · Recovery trend: IQVIA Institute for Human Data Science, Medicines Use and Spending in the U.S. 2023–2024
Because the fear narrative had replaced the evidence, the research dollars went elsewhere. For decades, NIH allocated $2 per menopause patient per year — compared to $175 for breast cancer, which affects far fewer people. Every year of that underfunding made the next clinical gap harder to close: the cardiovascular link unstudied, the cognitive connection untracked, the bone-loss timeline uncharted.
That is changing. Community pressure, capital validation, and the NASEM 2024 report — which recommended a dedicated $15.7B NIH women's health institute — are forcing the field to ask the questions it ignored for two decades.
NIH funding figures: NASEM 2024, A New Vision for Women's Health Research — $2/patient/yr menopause vs $175 breast cancer · Research gaps: PubMed · ClinicalTrials.gov · NIH RePORTER — menopause study counts 2000–2024 · Cognitive link: Alzheimer's Association 2024 Alzheimer's Disease Facts and Figures · two-thirds of Alzheimer's patients are women · Cardiovascular: American Heart Association Menopause & CVD Risk 2023
Policy is always the last force to arrive — because it needs everything else to be in place first. It needed a community large enough to be cited in Senate hearings. A capital wave large enough to create a political constituency. A research report with a dollar figure legislators could attach to the neglect. By 2021, all of that was finally in place.
What followed was more legislative action in five years than in the previous fifty combined: a Biden Executive Order, bipartisan Senate bills, the FDA removing its 2002 black box warning, Rhode Island becoming the first state to mandate menopause workplace support. By 2025, 12 US states had enacted protections. Each one made the next easier to pass.
Hover nodes to explore. Click to open the full interactive network.
Before there were studies, there was Reddit. 750,000 women spent 14 years documenting what was happening to their bodies in public. That became the signal. The clinical system caught up to data that patients had already collected.
23 years of under-treatment for 50 million women. The cost — in lost productivity, untreated heart disease, unnecessary cognitive decline — far exceeds what funding the research would have cost. Neglect compounds. Every year the gap stayed open, the bill got bigger.
Community first. Then capital. Then research. Then policy. None of it happened randomly — each step made the next one possible. Knowing that sequence is useful. It tells you where we are on the map right now, and what needs to happen next.
The FDA removed the black-box warning. States are passing laws. Non-hormonal treatments finally exist. Funding conversations are happening at the federal level for the first time. This window is real — but windows close. Whether the momentum translates into lasting infrastructure, or fades when the cultural moment moves on, is still an open question.
Endometriosis. ADHD in women. Postpartum depression. Long COVID hitting female patients hardest. The pattern — dismiss, underfund, let community carry the weight, eventually catch up — keeps repeating. Menopause became the clearest case study. The question now is whether we use what we learned here to move faster the next time.
Each force, explored in full — deeper narrative, milestones, and voices from the field.
I'm Adriana Sainz. Researcher. Designer. Building at the intersection of HCI and healthcare.
Women's health is one of the most overlooked design challenges in healthcare today. I turned one question into a 14-year data story. More coming.